缬沙坦联合泼尼松治疗特发性肺间质纤维化的临床观察
x
请在关注微信后,向客服人员索取文件
篇名: | 缬沙坦联合泼尼松治疗特发性肺间质纤维化的临床观察 |
TITLE: | |
摘要: | 目的:观察缬沙坦联合泼尼松对特发性肺间质纤维化的疗效和安全性。方法:50例特发性肺间质纤维化患者随机均分为对照组和观察组。对照组患者给予醋酸泼尼松片1~4周0.5 mg/(kg·d),5~12周0.25 mg/(kg·d),后以0.125 mg/(kg·d)维持治疗,每日2~3次;观察组患者在对照组治疗的基础上给予缬沙坦胶囊80 mg,口服,每日1次。两组患者疗程均为6个月。观察两组患者的临床疗效,治疗前后肺功能指标[用力肺活量(FVC)、最大呼气峰流速(PEFR)、第一秒用力呼气容积(FEV1)]、血清炎症因子指标[白细胞介素(IL)-13、IL-18、转化生长因子(TGF)-β1]水平,基质金属蛋白酶(MMP)-9、MMP-2含量及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两者患者肺功能指标、血清炎症因子指标、MMP-9、MMP-2含量比较,差异均无统计学意义(P>0.05);治疗后,两组患者肺功能指标均显著高于同组治疗前,且观察组高于对照组,血清炎症因子水平和MMP-9、MMP-2含量均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:缬沙坦联合泼尼松可显著改善特发性肺间质纤维化患者肺功能,降低血清炎性因子及基质金属蛋白酶的含量,疗效显著,安全性较好。 |
ABSTRACT: | OBJECTIVE:To observe the efficacy and safety of valsartan combined with prednisone in the treatment of idiopathic pulmonary fibrosis. METHODS: 50 patients with idiopathic pulmonary fibrosis were randomly divided into control group and observation group. Control group was orally given 0.5 mg/(kg·d) Prednisone acetate tablet in 1-4 weeks, then maintained with 0.125 mg/(kg·d) in 5-12 neeks, 2-3 times a day; observation group was additionally given 80 mg Valsartan capsule, orally, once a day. The treatment course for both groups was 6 months. Pulmonary function indicators [forced vital capacity (FVC), peak expiratory flow rate (PEFR),and forced expiratory volume in one second (FEV1)],serum inflammatory factor indicators [interleukin-13(IL-13), IL-18, transforming growth factor-β1(TGF-β1)] level, matrix metalloproteinase -9 (MMP-9), MMP-2 contents and the incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in the pulmonary function indicators, serum inflammatory factor indicators, MMP-9 and MMP-2 contents between 2 groups(P>0.05); after treatment, pulmonary function indicators in 2 groups were significantly higher than before, and observation group was higher than control group, MMP-9 and MMP-2 contents were significantly lower than before, and observation group was lower than control group(P<0.05). And there was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05). CONCLUSIONS: Valsartan combined with prednisone can significantly improve the pulmonary function of patients with idiopathic pulmonary fibrosis, and reduce the contents of serum inflammatory cytokines and matrix metalloproteinases, with good safety. |
期刊: | 2016年第27卷第6期 |
作者: | 霍艳霞,王志华,李爱敏,阮昕,宁学聪 |
AUTHORS: | HUO Yanxia,WANG Zhihua,LI Aimin,RUAN Xin,NING Xuecong |
关键字: | 特发性肺间质纤维化;缬沙坦;泼尼松;炎症因子;基质金属蛋白酶;疗效;安全性 |
KEYWORDS: | Idiopathic pulmonary fibrosis; Valsartan; Prednisone; Inflammatory factor; Matrix metalloproteinase; Efficacy; Safety |
阅读数: | 488 次 |
本月下载数: | 4 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!